Large holder update, amended
Open the filing on sec.gov
Valion Bio, Inc. (VBIO)
Nasdaq: VBIO · Electromedical & Electrotherapeutic Apparatus · San Antonio, TX · filing with the SEC since 2019
The companyfiscal 2024, as filed
Revenue$780,000-33.7%
Net income-$5.7M+31.4%
Earnings per share$-19.68+88.9%
Operating cash flow-$5.7M+32.7%
Cash$2.0M-41.0%
Debtn/a
Shareholders’ equity$2.5M-29.2%
Shares, diluted287,370+516.0%
Return on equity-52.8%
The recordfrom its filings
Filings in 202695
Newest filingNov 12 · SCHEDULE 13G/A
Annual reportMar 30, 2026
Quarterly reportAug 14, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted7
Filer category<br>Emerging growth company
Trailing twelve months to Jun 2026Net income -$18.8MCash from operations -$14.6Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Registration effective
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.